The Phase Angle as predictor of weight loss in endoscopic gastroplasty: preliminary results from a single center, randomized study

Aims Three different Endoscopic Gastroplasty (EG) techniques are mainly reported in literature: endoscopic sleeve gastroplasty (ESG), endoluminal vertical gastroplasty (EVG), and distal primary obesity surgery endoluminal (POSE-2). Our study aimed to assess biometrical parameters which could predict changes in weight loss at 6 months follow-up after EG.

Methods This was a single center, randomized study (ClinicalTrials.gov NCT04854317) of patients who underwent EG (through ESG or EVG or POSE-2) for the treatment of obesity. Outcomes included the efficacy of the three EG procedures at inducing weight loss, measured by the percentage of Total Body Weight Loss (%TBWL) and Excess Weight Loss (%EWL) ([Fig. 1]).

Fig. 1

Results Between July 2020 and October 2021, 90 obese (mean BMI 36.6 kg/m2) patients (mean age 46 y; females 87.5%; main obesity class: II in 58.3% cases; main comorbidity: hepatic steatosis in 70% cases) underwent EG through ESG or EVG or POSE-2. At 6 months, 70% patients attended their follow-up visit. They experienced 16% TBWL and 39.7% EWL, with no significant difference among the three techniques in both of parameters (p>0.62 in TBWL and p>0.94 in EWL ANOVA tests); 95.2% patients achieved at least 5% TBWL, and 85.7% achieved at least 25% EWL. All the body circumferences homogeneously decreased (p<0.001). By a linear regression analysis, a significant correlation between the Phase Angle and the %TBWL (p<0.05) and %EWL (p<0.05) was detected (Fig. 1).

Conclusions Our study confirms that ESG, EVG and POSE-2 are valuable EG procedures to reduce weight in obese patients. The Phase Angle could be considered a useful predictor of weight loss after the EG, at least in the short-term.

Conflicts of interest

Authors do not have any conflict of interest to disclose.

Publikationsverlauf

Artikel online veröffentlicht:
14. April 2023